HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial.
Listen to this summary
This phase 1 nonrandomized trial asked whether a single oral dose of HOPO 14-1, an orally administered actinide chelator, is safe and tolerable in healthy adults, and how it is absorbed and excreted. In 42 participants across seven dose levels (100 mg to 7500 mg), there were no serious adverse events or dose-limiting toxicities, with mild-to-moderate gastrointestinal effects (mainly diarrhea and vomiting) becoming most prominent at the highest doses. The drug was rapidly absorbed, showed greater-than-proportional increases in exposure at higher doses, and was eliminated mainly in feces, with minimal urinary excretion.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from JAMA
View all →Nov 19, 2026 · JAMA
Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology.
Nov 19, 2026 · JAMA
Medical Imaging and Pediatric and Adolescent Brain Tumor Risk.
Nov 17, 2026 · JAMA
Toward a Healthier Future Through Obesity Prevention and Care: The JAMA Summit Report on Obesity.
Nov 16, 2026 · JAMA
A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology.
Nov 15, 2026 · JAMA
Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial.
Nov 15, 2026 · JAMA
Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.
More in Thoracic Surgery (Cardiothoracic Vascular Surgery)
View all →Nov 19, 2026 · Lancet (London, England)
Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.
Nov 19, 2026 · Lancet (London, England)
Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).
Nov 19, 2026 · Lancet (London, England)
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.
Nov 19, 2026 · The New England journal of medicine
Assessing Multiple Treatment Regimens for Tuberculosis.
Nov 18, 2026 · The New England journal of medicine
Acute Respiratory Distress Syndrome.
Nov 17, 2026 · Lancet (London, England)
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


